Page 1

BIOARCTIC Eisai initiates Biologics License Application of lecanemab in the US earlier than expected ● EVENTS DURING THE THIRD QUARTER 2021 Eisai has initiated a rolling submission for the US FDA Biologics License Application of lecanemab , under the accelerated approval pathway . The objective is for lecanemab to be approved for the treatment of patients with early Alzheimer's disease . ● FINANCIAL SUMMARY JULY - SEPTEMBER 2021 Net revenues for the period amounted to MSEK 4.0 ( 10.5 ) Operating profit amounted to MSEK -37.4 ( -20.7 ) ● ● ● Data from the Phase 2b open - label extension study of lecanemab presented at the Alzheimer's Association International Conference provided further support for the clinical effects of the drug candidate . The baseline characteristics for the Clarity AD and AHEAD 3-45 Phase 3 studies were also presented , as well as the possibility of using specific blood biomarkers to monitor the effects of the drug in individual patients . FINANCIAL SUMMARY JANUARY - SEPTEMBER 2021 Net revenues for the period amounted to MSEK 18.4 ( 54.0 ) Operating profit amounted to MSEK -100.4 ( -54.9 ) ● INTERIM REPORT Profit for the period amounted to MSEK -37.6 ( -20.7 ) and earnings per share before and after dilution were SEK -0.43 ( -0.23 ) Cash flow from operating activities amounted to MSEK -34.8 ( -9.4 ) Cash and cash equivalents at the end of the period amounted to MSEK 892 ( 1,036 ) Profit for the period amounted to MSEK -100.8 ( -55.3 ) and earnings per share before and after dilution were SEK -1.15 ( -0.63 ) Cash flow from operating activities amounted to MSEK -101.2 ( -65.6 ) Cash and cash equivalents at the end of the period amounted to MSEK 892 ( 1,036 ) KEY FINANCIAL PERFORMANCE INDICATORS MSEK Net revenues Other operating income Operating profit / loss Operating margin , % Profit / loss for the period Earnings per share before dilution , SEK Earnings per share after dilution , SEK Equity per share , SEK Cash flow from operating activities Cash flow from operating activities per share , SEK Equity / assets ratio , % Return on equity , % Share price at the end of the period , SEK Q3 July - September 2021 2021 4.0 0.7 -37.4 neg -37.6 -0.43 -0.43 9.17 -34.8 -0.39 86.3 -4.55 162.60 2020 10.5 0.9 -20.7 neg -20.7 -0.23 -0.23 10.45 -9.4 -0.11 85.5 -2.22 88.95 Jan - Sep 2021 18.4 3.0 -100.4 neg -100.8 -1.15 -1.15 9.17 -101.2 -1.15 86.3 -11.76 162.60 2020 54.0 2.2 -54.9 neg -55.3 -0.63 -0.63 10.45 -65.6 -0.74 85.5 -5.84 88.95 Jan - Dec 2020 62.3 3.6 -85.0 neg -68.5 -0.78 -0.78 10.30 -92.3 -1.05 86.4 -7.28 95.40 Unless otherwise stated , this Interim report refers to the Group . Figures in parentheses refer to the corresponding period last year . The amounts stated are rounded , which sometimes leads to some totals not being exact . Q3 July - September 2021 1